1. Home
  2. SPRO vs MPAA Comparison

SPRO vs MPAA Comparison

Compare SPRO & MPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • MPAA
  • Stock Information
  • Founded
  • SPRO 2013
  • MPAA 1968
  • Country
  • SPRO United States
  • MPAA United States
  • Employees
  • SPRO N/A
  • MPAA N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • MPAA Auto Parts:O.E.M.
  • Sector
  • SPRO Health Care
  • MPAA Consumer Discretionary
  • Exchange
  • SPRO Nasdaq
  • MPAA Nasdaq
  • Market Cap
  • SPRO 164.4M
  • MPAA 188.9M
  • IPO Year
  • SPRO 2017
  • MPAA 1994
  • Fundamental
  • Price
  • SPRO $2.91
  • MPAA $12.39
  • Analyst Decision
  • SPRO Buy
  • MPAA
  • Analyst Count
  • SPRO 4
  • MPAA 0
  • Target Price
  • SPRO $5.00
  • MPAA N/A
  • AVG Volume (30 Days)
  • SPRO 1.6M
  • MPAA 338.6K
  • Earning Date
  • SPRO 08-04-2025
  • MPAA 06-09-2025
  • Dividend Yield
  • SPRO N/A
  • MPAA N/A
  • EPS Growth
  • SPRO N/A
  • MPAA N/A
  • EPS
  • SPRO N/A
  • MPAA N/A
  • Revenue
  • SPRO $44,584,000.00
  • MPAA $757,354,000.00
  • Revenue This Year
  • SPRO N/A
  • MPAA $7.74
  • Revenue Next Year
  • SPRO N/A
  • MPAA $5.00
  • P/E Ratio
  • SPRO N/A
  • MPAA N/A
  • Revenue Growth
  • SPRO N/A
  • MPAA 5.53
  • 52 Week Low
  • SPRO $0.51
  • MPAA $5.16
  • 52 Week High
  • SPRO $3.09
  • MPAA $12.72
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 71.62
  • MPAA 67.21
  • Support Level
  • SPRO $2.79
  • MPAA $9.95
  • Resistance Level
  • SPRO $3.03
  • MPAA $10.43
  • Average True Range (ATR)
  • SPRO 0.12
  • MPAA 0.63
  • MACD
  • SPRO -0.08
  • MPAA 0.21
  • Stochastic Oscillator
  • SPRO 43.75
  • MPAA 93.33

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About MPAA Motorcar Parts of America Inc.

Motorcar Parts of America Inc is a supplier of automotive aftermarket non-discretionary replacement parts and test solutions and diagnostic equipment. It operate in the non-discretionary automotive aftermarket for replacement hard part in North America and includes products such as light-duty rotating electrical products, wheel hub products, brake-related products, and turbochargers. In addition, it sell test solutions and diagnostic equipment. The company operates in three segments Hard Parts, Test Solutions and Diagnostic Equipment, and Heavy Duty. Key revenue is generated from Hard Parts, which includes (i) light duty rotating electric products such as alternators and starters, (ii) wheel hub products, (iii) brake-related products, including brake calipers, brake boosters, brake rotors.

Share on Social Networks: